Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 108,00 € (+41,31%). La mediana è 103,84 € (+35,86%).
| Acquista |
20 |
| Mantieni |
4 |
| Vendi |
0 |
Discussioni nella community
- Europäische Aktien
Ich suche derzeit nach guten Investitionsmöglichkeiten in Europa, um meine US Gewichtung etwas nach unten zu bringen. Ich schaue mir gerade die London Stock Exchange und Kongsberg Gruppen an. Bereits…
u user_ce10af IV in Schnack
0 13 - CureVac -> Biontech
Hi Leute, ich habe die Tauschangebot von BionTech angenommen. Super Deal !!! aber wie bilde ich das ganze jetzt in Parqet ab? Ist Comdirect jetzt funktioniert der Autosync hier nicht da ich keine…
Flo IV in Schnack 0 5 - BioNtech 10x Kandidat?
Eure Meinung zu Biontech interessiert mich sehr. Pipeline hat über 20 Medikamente in Phase 2 oder Phase 3 Studien. Dieses Jahr wird erwartet die erste Zulassung für ein Lungenkrebs Medikament zu…
u user_ce10af IV in Schnack
0 10 - Delisting Curevac
Hallo, ich hatte nicht mitbekommen , dass ich selbst aktiv werden musste um meine Curevac Aktien gegen Biontec zu tauschen. Es kam von TRADE REPUBLIC auch kein Hinweis. Gestern dann bekam ich diese…
WW Wolf W. II in Schnack
0 6 - Buchungsprobleme Biontech Curevac Übernahme
Hallo, ich besaß vor der Übernahme Curevac Aktien und gleichzeitig auch Aktien von Biontech. Die Curevac-Aktien wurden ja bekanntlich umgewandelt und ich bekam Biontech-Bruchstücke. Diese wurden dann…
J Julian V in Schnack
0 3
Notizie Vai al feed delle notizie
Biontech records share plunge and closes sites after founders' exit
Biontech has lost massive market value since the COVID peak and is currently trading at around €80, about a quarter of its record high. Founders Uğur Şahin and Özlem Türeci are leaving the company to pursue new research projects, which further weighed on the share price. Biontech is now focusing on research into cancer vaccines and immunotherapies, but at the same time is shutting sites in Germany, risking loss of know‑how and staff despite large cash reserves. » Altro su t-online.de
BioNTech meets minimum acceptance condition of exchange offer for CureVac
BioNTech announced that by the expiration of the original deadline 184,071,410 CureVac shares (about 81.74% of the issued and outstanding shares) were validly tendered, thereby satisfying the minimum acceptance condition. All tendered shares were accepted; the post-offer period runs until Thursday, 18 December 2025, 6:01 a.m. CET, during which additional shareholders may tender. BioNTech will issue BioNTech ADSs or cash compensation payments for fractions to the tendering CureVac shareholders; non-tendering shareholders will also receive ADSs/cash compensation as part of the post-offer reorganization and their shares will subsequently no longer be tradable on a national exchange. Dutch withholding tax of 15% may generally apply to the BioNTech ADSs issued to non-tendering holders. » Altro su finanzen.net
Biontech starts public exchange offer for Curevac shares
After approval by the Federal Cartel Office, Biontech is launching a public exchange offer for all outstanding Curevac shares. Curevac shareholders can swap their securities for Biontech ADS, provisionally valued at about $5.46 per Curevac share; the final exchange value will be set five days before the offer ends on 3 December. The management board and supervisory board of Curevac recommend the swap, and major shareholders holding more than 57 percent have already agreed; a minimum acceptance threshold of 80 percent is required. » Altro su finanzen.net
BioNTech launches public exchange offer for all CureVac shares
BioNTech has launched a public exchange offer for all outstanding CureVac shares, converting each CureVac share into BioNTech-ADSs worth approximately $5.46. The exchange ratio will be determined by a VWAP-based adjustment mechanism; the offer is scheduled to run until December 3, 2025 (9:00 a.m. ET). The transaction is subject to conditions such as a minimum acceptance threshold of 80% (75% in certain circumstances) and regulatory approvals; BioNTech plans, upon closing, to fully acquire and restructure CureVac to strengthen its mRNA oncology pipeline. » Altro su finanzen.net
Biontech allowed to acquire Curevac, antitrust authority sees no competitive disadvantage
The Bundeskartellamt has approved Biontech's planned acquisition of Curevac and does not expect any restriction of innovation competition. Biontech intends to acquire Curevac through a share swap and says it plans to complete the deal by the end of the year. The authority stresses that Curevac currently has no approved marketed products and that the research pipelines of the two companies show little overlap, while Biontech already has market presence with Comirnaty. » Altro su n-tv.de
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 1,29 Mld | 15,12% |
| Utile lordo | 1,19 Mld | 13,48% |
| Utile netto | 184,5 Mln | 742,86% |
| EBITDA | 562,6 Mln | 276,83% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 19,16 Mld € |
Numero di azioni | 247,93 Mln |
Massimo/minimo a 52 settimane | 112,95 € - 72,43 € |
| Dividendi | No |
Beta | 1,33 |
Rapporto P/E | -13,07 |
Rapporto PEG | 0,13 |
Rapporto P/B | 1,08 |
Rapporto P/S | 7,91 |
Profilo aziendale
BioNTech SE, una società di biotecnologie, sviluppa e commercializza immunoterapie per il cancro e altre malattie infettive. La società sta sviluppando i candidati prodotto FixVac, tra cui BNT111, in sperimentazione clinica di Fase II per il melanoma avanzato; BNT112, in sperimentazione clinica di Fase I/IIa per il cancro alla prostata; BNT113, in sperimentazione clinica di Fase II per il trattamento dei tumori alla testa e al collo HPV+; BNT114, in sperimentazione clinica di Fase I per il cancro al seno triplo negativo; BNT115, in sperimentazione clinica di Fase I per il cancro ovarico; e BNT116, un prodotto in fase preclinica per il carcinoma polmonare non a piccole cellule. Sviluppa inoltre immunoterapie specifiche per neoantigeni, come Autogene cevumeran (BNT122), in sperimentazione clinica di Fase II per il melanoma di prima linea, nonché in sperimentazione clinica di Fase 1a/1b per il trattamento di più tumori solidi; immunoterapia intratumorale a mRNA comprendente SAR441000, in sperimentazione clinica di Fase I per i tumori solidi; e BNT141 e BNT142, in sperimentazione clinica di Fase I per il trattamento di più tumori solidi. Inoltre, la società sviluppa i RiboCytokine, che includono BNT151, BNT152 e BNT153 per il trattamento dei tumori solidi; immunoterapie con cellule T con recettore antigenico chimerico, come BNT211 per il trattamento di più tumori solidi, e BNT221 per altri tumori; e immunomodulatori checkpoint costituiti da GEN1046 e GEN1042, in sperimentazione clinica di Fase I/II per il trattamento dei tumori solidi. Sviluppa inoltre BNT321, un anticorpo monoclonale IgG1 in sperimentazione clinica di Fase II per il cancro al pancreas; BNT411, un immunomodulatore a piccola molecola candidato prodotto per i tumori solidi; un vaccino profilattico contro COVID-19 e influenza; e immunoterapie per malattie infettive e terapie sostitutive proteiche per malattie rare. La società ha collaborazioni con Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; e Regeneron Pharmaceuticals, Inc. BioNTech SE è stata costituita nel 2008 e ha sede a Magonza, in Germania.
| Nome | BioNTech (ADR) |
| CEO | Ugur Sahin |
| Sede centrale | Mainz,
rp Germania |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 25/03/2010 |
| Dipendenti | 7807 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | BNTX |
XETRA | 22UA.F |
Frankfurt | 22UA.F |
Düsseldorf | 22UA.DU |
Hamburg | 22UA.HM |
London | 0A3M.L |
SIX | 22UA.SW |
München | 22UA.MU |
Wien | BNTX.VI |